QureTech’s GmPcides represents an innovative class of small-molecule synthetic antibiotics that effectively target drug-resistant bacteria, including MRSA, with no evidence of resistance development.

The European patent approval, which provides protection until 2041, marks a significant milestone for the company, it states. The patent has already been approved in China and is pending in the USA, India, and Japan.

“The patent ensures strong protection for GmPcides, which is crucial in our industry, and represents a significant step toward making our compounds available to patients in need of effective treatment for drug-resistant bacteria,” says Markus Thor, CEO of QureTech Bio.

The European Patent Office (EPO) granted the patent application titled “Ring-fused 2-pyridone compounds, methods for their preparation, and their use in the treatment and/or prevention of diseases involving Gram-positive bacteria” on February 26.